Closed · RFA-DA-11-004 · CFDA 93.279 · Discretionary

Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR [R41]

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $300K
Award range
Closed
Status
January 13, 2011
Close date
-
Expected awards

The verdict

Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR [R41] is a closed discretionary listing from National Institutes of Health that offered Up to $300,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $300K
award range
Closed
application status
93.279
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Pharmacological Development of Treatment Agen… is closed (last close January 13, 2011). The parent program page for CFDA 93.279 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed January 13, 2011

Posted Aug 26 Closes Jan 13

Est. Total Funding

$1,500,000

Instrument

Grant

Description

Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) is to facilitate the development of new, more effective treatments for tobacco dependence. Mechanism of Support. This FOA will utilize the STTR (R41) grant mechanisms for Phase I applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 4-7 projects awarded as a result of this announcement is $1,500,000 for fiscal year 2011. Future year amounts will depend on annual appropriations. Budget and Project Period. For these Phase I projects, budgets up to $300,000 total costs for a time period of up to one year may be requested.

Small-business / for-profit corridor · RFA-DA-11-004

Pharmacological Development of Treatment Agen… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Pharmacological Development of Treatment Agen… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.279 may publish future NOFOs under the same assistance listing. Open program
  • Drug Abuse Research Programs indexes 170 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants